
Case Studies in Designing Clinical Trials in Rare Disease



Melanie Quintana, PhD melanie@berryconsultants.com CTMC 2018

Dominantly Inherited Alzheimer's


- Rare genetic form of Alzheimer's (<1% of total Alzheimer's population)
- Early age of onset: 30-50
- Goal: Does the treatment slow cognitive progression?





GNE Myopathy

- Rare genetic muscle disease
- Slowly progressive muscle weakness and atrophy effecting different muscle groups at different stages of the disease
- Goal: Does the treatment slow decline of muscle strength?





Fibrodysplasia Ossificans Progressiva (FOP)

- Rare genetic connective tissue disease causing fibrous tissue to be ossified spontaneously or when damaged.
- Median age at diagnosis is 5 years
- Goal: Does the treatment reduce the amount of bone growth?





Complexity in Rare Disease


- Heterogeneity in progression
- Large variability in key clinical endpoints
- Different endpoints are effected at different stages of the disease
- Common Solutions:

setting!

- Enroll a more homogenous subset
- Enroll a large enough sample size to overcome heterogeneity
- Both not ideal in a rare disease



Solutions for Rare Disease



- Natural History Studies -- Know what you are working with!
- Innovative Designs
 - More powerful analysis methods
 - Adaptive designs with frequent interims
 - Use all available data



NATURAL HISTORY STUDIES



Natural History Studies

- Understand behavior of candidate primary endpoints
- Create Realistic Evidence-Based Virtual Patient Simulator
- Understand Power / Operating Characteristics of Proposed Design



GNE Natural History Data


- Sample Size: 38 Patients
- Visits: Every 3-6 months
 - Number of months from baseline per patient ranges from 0-32
- Measurements taken on possible primary endpoints:
 - Six minute walk
 - Quantitative Muscle Assessment (QMA) for multiple muscle groups



Possible Primary Endpoints: 6 Min. Walk


Raw Scores

Change from Baseline + Model Fit





Possible Primary Endpoints: Upper Extremity Composite Subset*





Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy

Study did not meet its primary endpoint

NOVATO, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that a Phase 3 study evaluating aceneuramic acid extended release (Ace-ER) in patients with GNE Myopathy (GNEM) did not achieve its primary endpoint of demonstrating a statistically significant difference in the upper extremity muscle strength composite score compared to placebo. The study also did not meet its key secondary endpoints. Adverse events were generally balanced between Ace-ER and placebo and safety was consistent with previously released Ace-ER data. Ultragenyx plans to discontinue further clinical development of Ace-ER.

"We are disappointed by these results, as we had hoped that Ace-ER would offer a new option for GNEM patients. We would like to thank the patients, caregivers, and investigators involved in the Ace-ER development program," said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. "This outcome does not affect our overall strategy, as the company moves forward with multiple preclinical and clinical programs and regulatory filings."

The Phase 3 Ace-ER study enrolled 89 adults with GNEM able to walk \geq 200 meters in the six minute walk test. Patients were randomized 1:1 to Ace-ER at a dose of 6g/day or placebo for 48 weeks. The study did not meet the primary endpoint of demonstrating a statistically significant improvement in UEC score (+0.74 kg, p=0.5387) for Ace-ER treated patients (n=45, -2.25 kg) compared to placebo (n=43, -2.99 kg) patients for the change from baseline to 48 weeks. There were three pre-specified key secondary endpoints, including the lower extremity muscle strength composite score as measured by hand-held dynamometry (HHD), physical functioning using the Mobility domain of the GNE Myopathy-functional activity scale (GNEM-FAS), and a measure of muscle strength in knee extensors. The study did not meet any of these key secondary endpoints.




Natural History Studies

- Understand behavior of candidate primary endpoints
- Create Realistic Evidence-Based Virtual Patient Simulator
- Understand Power / Operating Characteristics of Proposed Design




Virtual Patient Simulations






DIAN Observational Data






DIAN Disease Progression






Natural Cognitive Decline




Berry Consultants Statistical Innovation





Subject 1:


Subject-level random effect: -.8 Years since onset at enrollment: 5 Enrolled to treatment group
















CTMC 2018

Berry Consultants Statistical Innovation





CTMC 2018

Berry Consultants Statistical Innovation

Natural History Studies

- Understand behavior of candidate primary endpoints
- Create Realistic Evidence-Based Virtual Patient Simulator
- Understand Power / Operating Characteristics of Proposed Design




DIAN Initial Proposed Design

Proposed Design:

- 80 subjects per arm randomized 3:1 (Treatment: Control)
- Max length of follow-up: 4 years
- Primary Analysis Method: MMRM



Power DIAN Trial



DESIGN INNOVATIONS




Common Primary Analysis: MMRM

- MMRM Issues :
 - Dilution of effect due to subjects not expected to progress (very early or very late disease)
 - Test effect at a single time point



Disease Progression Modification Analysis

• DPMA: Assume proportional treatment effect at each EYO



31


Disease Progression Modification Analysis

- DPMA: Assume proportional treatment effect at each EYO
 - Uses all timepoints
 - Adjusts for expected decline given EYO
 - Incorporate differential follow-up: Due to missing data; early interim analyses, extended follow-up
 - Extended follow-up = Greater Power




DPMA vs. MMRM

Power DIAN Trial




DIAN Adaptive Platform Trial





Borrowed Controls


Power DIAN Trial



Berry Consultants Statistical Innovation

Frequent Interim Analyses

Power DIAN Trial





Summary

- Natural History Studies + Clinical Trial Simulation = More Informed Trial Design!
 – Original DIAN Power = < 20%
- Need for better analysis methods that use all available data and adjust for expected progression
 - Innovative DPMA + Shared PBO leads to increase in DIAN power from <20% to > 80%!





